Kamagra repose sur le sildénafil comme principe actif, avec un mode d’action identique à celui du Viagra. La forme galénique en gel oral permet une absorption plus rapide et une concentration plasmatique maximale plus précoce que les comprimés. Le mécanisme implique l’inhibition compétitive de la PDE5, entraînant une relaxation musculaire lisse locale et une vasodilatation ciblée. La demi-vie courte, environ 4 heures, limite la durée d’action. L’élimination se fait après métabolisme hépatique, impliquant majoritairement le CYP3A4. L’incidence d’effets indésirables comprend céphalées, rougeurs et congestion nasale, de façon transitoire. Dans les comparatifs pharmacologiques, acheter kamagra sans ordonnance est associé aux présentations galéniques alternatives disponibles.

Figo2009.org.za

XIX FIGO WORLD CONGRESS OF GYNECOLOGY AND OBSTETRICS
INDUSTRY-SPONSORED SYMPOSIA
Monday, 5 October 2009
13h00-14h15
Ballroom East (CTICC)
Contraception and Beyond: Evidence-based Indications for LNG-IUS
1. Wider Use of Intrauterine Contraception - David Grimes
2. The LNG-IUS in Heavy Menstrual Bleeding: First-line Treatment Based on Comprehensive Clinical Data - Anita Nelson 3. Safety and Efficacy of Consecutive Use of the LNG-IUS - Confirmed by a New Study -Kristina Gemzell-Danielsson Symposium sponsored by Bayer Schering Pharma
Ballroom West (CTICC)
The Role of GARDASIL™ in Reducing the Global Burden of Cervical Cancer and
Other HPV-Related Diseases
1. Opening Remarks – Lynette Denny, South Africa
2. Global HPV Epidemiology and Burden of Disease - Lynette Denny, South Africa3. Gardasil Efficacy and Recent Clinical Data - Suzanne M. Garland, Australia 4. MSD’s Commitment: Access to Gardasil in the Developing World - Carlos Sattler, USA Symposium sponsored by MSD
Tuesday, 6 October 2009
13h00-14h15
Ballroom East (CTICC)
Innovation in Contraception
1. Ethinylestradiol 20mcg/Drospirenone 3mg Administered in a 24/4 Regimen: A New OC
Goes Beyond Contraception - Joachim Marr and Lorraine Dennerstein
2. A New OC Concept with Additional Benefit - Wolfgang Holzgreve and Klaus Pietrzik Symposium sponsored by Bayer Schering Pharma
Ballroom West (CTICC)
Overactive Bladder: TIME to take notice
Chairman’s Introduction
1. The Burden and Implications of OAB – Linda Cardozo, UK2. Initial Diagnosis and Assessment of Women with LUTS - Mickey Karram, USA3. Making Sure We Understand Our Patient’s Needs – Peter de Jong, South Africa 4. Ensuring Successful Management with Pharmacotherapy - Willy Davilla, USA Symposium sponsored by Astellas Pharma
Wednesday, 7 October 2009
13h00-14h15
Ballroom East (CTICC)
Evolution of a Revolution: Introducing a New Class of Oral Contraceptive
1. Introducing E2V/DNG - Ian Fraser2. E2V/DNG: Contraceptive Efficacy and Safety Data - Jeffrey T. Jensen 3. First Experience with the Estradiol Based Combined Oral Contraceptive E2V/DNG - Diana Mansour Symposium sponsored by Bayer Schering Pharma
Ballroom West (CTICC)
Effective Solutions for Enhanced Obstetric Management
1. New Ultrasound Technologies in Assisted Reproductive Medicine SonoAVC - Nick Raine
Fenning, Nottingham, UK
2. Enhancing the Monitoring Experience from Antepartum through to Postpartum - Philippe Barjot, Caen, France 3. Improving Obstetric Workflow, Archiving and Reporting - Philippe Barjot, Caen, France Symposium sponsored by GE Healthcare
Thursday, 8 October 2009
13h00-14h15
Ballroom East (CTICC)
Improving Women's Healthcare - a Contemporary View
Chair: Jennifer Blake
1. Progestins - An Important Versatile Class – Peter Rogers
2. Specialised Progestins I - Dienogest in Endometriosis - Alfred Mueck3. Specialised Progestins II – Drospirenone in Menopause - Tommaso Simoncini Symposium sponsored by Bayer Schering Pharma
Ballroom West (CTICC)
Cervarix®: Focusing on the Global Needs of Cervical Cancer Vaccination
1. Welcome and Introduction – Anne Szarewski, UK and Hugues Bogaerts, Belgium
2. The Relevance of the HPV Type Distribution in Cervical Cancer – F. Xavier Bosch, Spain3. Understanding the Immunological Potential of HPV Vaccines – Peter L. Stern, UK4. Cervarix®: The Benefits to Girls and Women: From Clinical Trials to Clinical Practice – Anne Symposium sponsored by GlaxoSmithKline

Source: http://www.figo2009.org.za/ScientificProgramme/IndustrySponsoredSymposiaProg_Sep.pdf